中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2013年
13期
792-795
,共4页
培美曲塞%卡铂%非小细胞型肺癌
培美麯塞%卡鉑%非小細胞型肺癌
배미곡새%잡박%비소세포형폐암
pemetrexed disodium%carboplatin%non-small cell lung cancer
目的：培美曲塞（PEM）是一种多靶点抗叶酸化疗药，目前已成为晚期非小细胞肺癌二线治疗的标准药物。本研究回顾分析培美曲塞联合铂类治疗非小细胞肺癌的临床疗效及不良反应。方法：选择经病理学证实的非小细胞型肺癌患者40例，予以培美曲塞二钠500 mg/m2静脉滴注，联合卡铂常规剂量第1d、21d为1周期，每例患者至少化疗2个周期（观察组），并与吉西他滨（GEM）+卡铂方案做对照（对照组），评价疗效及不良反应。结果：治疗2个周期后PEM 组有效率50%，GEM 组有效率45%。主要为骨髓抑制及胃肠道反应，PEM 组的骨髓抑制、胃肠道反应、AST、尿素氮及皮疹、脱发的发生率明显低于GEM 组，2组不良反应比较差异有统计学意义（P<0.05）。结论：培美曲塞二钠联合卡铂治疗非小细胞型肺癌临床疗效明显，不良反应少。
目的：培美麯塞（PEM）是一種多靶點抗葉痠化療藥，目前已成為晚期非小細胞肺癌二線治療的標準藥物。本研究迴顧分析培美麯塞聯閤鉑類治療非小細胞肺癌的臨床療效及不良反應。方法：選擇經病理學證實的非小細胞型肺癌患者40例，予以培美麯塞二鈉500 mg/m2靜脈滴註，聯閤卡鉑常規劑量第1d、21d為1週期，每例患者至少化療2箇週期（觀察組），併與吉西他濱（GEM）+卡鉑方案做對照（對照組），評價療效及不良反應。結果：治療2箇週期後PEM 組有效率50%，GEM 組有效率45%。主要為骨髓抑製及胃腸道反應，PEM 組的骨髓抑製、胃腸道反應、AST、尿素氮及皮疹、脫髮的髮生率明顯低于GEM 組，2組不良反應比較差異有統計學意義（P<0.05）。結論：培美麯塞二鈉聯閤卡鉑治療非小細胞型肺癌臨床療效明顯，不良反應少。
목적：배미곡새（PEM）시일충다파점항협산화료약，목전이성위만기비소세포폐암이선치료적표준약물。본연구회고분석배미곡새연합박류치료비소세포폐암적림상료효급불량반응。방법：선택경병이학증실적비소세포형폐암환자40례，여이배미곡새이납500 mg/m2정맥적주，연합잡박상규제량제1d、21d위1주기，매례환자지소화료2개주기（관찰조），병여길서타빈（GEM）+잡박방안주대조（대조조），평개료효급불량반응。결과：치료2개주기후PEM 조유효솔50%，GEM 조유효솔45%。주요위골수억제급위장도반응，PEM 조적골수억제、위장도반응、AST、뇨소담급피진、탈발적발생솔명현저우GEM 조，2조불량반응비교차이유통계학의의（P<0.05）。결론：배미곡새이납연합잡박치료비소세포형폐암림상료효명현，불량반응소。
Objective: Pemetrexed (PEM) is a multi-targeted chemotherapeutic agent for antifolate drugs. PEM has become the standard agent for the second-line treatment of advanced non-small cell lung cancer (NSCLC). This study aims to review and analyze the clinical efficacy and adverse reactions of PEM combined with carboplatin with respect to NSCLC treatment. Methods: A total of 40 patients suffering from NSCLC were selected and confirmed by pathology. On the first day of treatment, the conventional 500 mg/m2 dose of pemetrexed disodium was infused intravenously. On the second day, a combined therapy with carboplatin was conducted based on the conventional dose for a 21-day cycle with at least two cycles for each patient. The therapeutic efficacy and adverse reactions were evaluated and were compared with the proposed regimen of gemcitabine (GEM) combined with carboplatin. Results: After two cycles of the treatment, the curative effects of the PEM and GEM groups were 50% and 45%, respectively. The main adverse reactions are bone marrow suppression and gastrointestinal reactions. The incidence rates of bone marrow suppression, gastrointestinal reactions, amisulpride/AST, urea nitrogen, rash, and hair loss were obviously lower in the PEM group than in the GEM group. Statistically significant differences in adverse reaction were found between the two groups (P<0.05). Conclusion: The use of the combination regimen of PEM with carboplatin showed significantly more clinical effects and less adverse reactions for NSCLC treatment.
